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Abstract
Background: Prediction of clinical outcome in the acute stage of ischaemic stroke can be difficult when based on
patient characteristics, clinical findings and on non-contrast CT. CT perfusion and CT angiography may provide
additional prognostic information and guide treatment in the early stage. We present the study protocol of the
Dutch acute Stroke Trial (DUST). The DUST aims to assess the prognostic value of CT perfusion and CT angiography in
predicting stroke outcome, in addition to patient characteristics and non-contrast CT. For this purpose, individualised
prediction models for clinical outcome after stroke based on the best predictors from patient characteristics and
CT imaging will be developed and validated.
Methods/design: The DUST is a prospective multi-centre cohort study in 1500 patients with suspected acute ischaemic
stroke. All patients undergo non-contrast CT, CT perfusion and CT angiography within 9 hours after onset of the
neurological deficits, and, if possible, follow-up imaging after 3 days. The primary outcome is a dichotomised score
on the modified Rankin Scale, assessed at 90 days. A score of 0–2 represents good outcome, and a score of 3–6
represents poor outcome. Three logistic regression models will be developed, including patient characteristics and
non-contrast CT (model A), with addition of CT angiography (model B), and CT perfusion parameters (model C).
Model derivation will be performed in 60% of the study population, and model validation in the remaining 40% of
the patients. Additional prognostic value of the models will be determined with the area under the curve (AUC)
from the receiver operating characteristic (ROC) curve, calibration plots, assessment of goodness-of-fit, and likelihood
ratio tests.
Discussion: This study will provide insight in the added prognostic value of CTP and CTA parameters in outcome
prediction of acute stroke patients. The prediction models that will be developed in this study may help guide
future treatment decisions in the acute stage of ischaemic stroke.
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Background
Stroke is the fourth leading cause of death and the most
common cause of long term disability [1]. Around 20%
of stroke patients die within one year after the stroke
event [1]. Prediction of long-term clinical outcome in
acute ischaemic stroke is important, but not easy when
based on patient characteristics, clinical findings and
non-contrast CT (NCCT). Improving outcome predic-
tion may help determine the optimal treatment strategy
in the acute stage, when clinicians need to weigh pos-
sible benefit and harmful side effects of treatment. For
treatment with intravenous thrombolysis with recombinant
tissue type plasminogen activator (IV-rtPA) for example,
time since stroke onset is the main safety criterion for
patient selection. Additional imaging techniques might
improve risk stratification.
CT imaging plays a critical role in the acute stage of
stroke assessment as it is faster and more feasible than
MRI and available 24/7 in stroke clinics worldwide. The
NCCT can easily be extended with CT perfusion (CTP)
and CT angiography (CTA) within a 5- to 10-minute
examination [2] and has been successfully incorporated
into acute stroke imaging protocols [3-5]. CTP and CTA
may offer important parameters for predicting stroke out-
come. CTP offers the possibility to differentiate reversible
from irreversible ischaemic brain tissue and can give infor-
mation on the permeability of the blood brain barrier
[2,6-11]. On CTA, the location and extent of the arterial
occlusion, collateral circulation, extracranial stenosis, and
ischaemic changes within brain tissue can be visualised
[12-17]. These parameters, including patient characteristics
and NCCT findings, have been described separately in
studies with MRI and/or CT, but have not been combined
in one study to assess their combined predictive value.
The Dutch acute Stroke Trial (DUST) aims to improve
prediction of outcome in patients with acute ischaemic
stroke. For this purpose, we will assess the additional
predictive value of CTP and CTA to the conventional
determinants of patient characteristics and NCCT find-
ings. We will develop an individualised prediction model
for clinical outcome after stroke based on patient char-
acteristics and CT parameters. This prediction model
may help guide clinicians in making better treatment
decisions.
Methods/design
Study design
The DUST is a prospective multicentre observational
cohort study with the aim to include 1500 patients with
a suspected acute ischaemic stroke. Six university and 8
non-university hospitals in The Netherlands participate
in this study. On admission, baseline characteristics are
collected, laboratory testing is performed, and patients
undergo CT imaging consisting of NCCT, CTP and
CTA (see Figure 1). The following 3 days, additional
patient characteristics and results of laboratory tests
are collected. When possible, follow-up imaging is per-
formed around 3 days after admission to evaluate if there
is an infarct and if other admission imaging findings have
changed. Information on the final diagnosis (or death) is
collected at discharge. Clinical outcome, as primary study
outcome, is assessed by the modified Rankin Scale (mRS)
at 90 days.
Inclusion and exclusion criteria
All patients with a clinical diagnosis of acute ischaemic
stroke (both anterior and posterior circulation) are in-
cluded if the following criteria are met: 1) older than
18 years, 2) National Institutes of Health Stroke Scale
(NIHSS) ≥2, or 1 if an indication for IV-rtPA is present
(e.g. isolated aphasia), 3) acute neurological deficit of less
than nine hours of duration. Patients with an unknown
time of symptom onset, i.e. patients who wake up or are
found with stroke symptoms, can be included if the time
from going to sleep or being last seen without symptoms,
until imaging is less than 9 hours. Patients are excluded
from the study if another diagnosis on admission NCCT
explains the neurological deficits (e.g. intracerebral haem-
orrhage, subarachnoid haemorrhage, or tumour). Further-
more, patients cannot be included if they have a known
contrast allergy or previously known renal failure at the
time of admission.
Baseline clinical and laboratory data collection
Clinical data collection at baseline
After inclusion, details on stroke symptoms are collected,
including time of symptom onset, time of arrival at the
hospital, and stroke severity determined by the NIHSS
[18]. As patients with an already poor functional status
prior to the stroke symptoms are less likely to have a good
outcome, pre-existing functional status is summarised in
an mRS score [19]. Patient characteristics including blood
pressure, pulse rate, length, weight, temperature, any medi-
cation use, and medical history are also collected. Regard-
ing medical history, information is recorded about the
presence of cardiovascular risk factors such as hyperten-
sion, diabetes mellitus, hyperlipidemia, prior vascular dis-
ease (including stroke and myocardial infarction), alcohol
intake, smoking, and family history of vascular disease in
first grade relatives. Furthermore, data on whether or not
the patient is treated with IV-rtPA, intra-arterial thromb-
olysis (IAT), or mechanical thrombectomy, and time from
stroke onset to treatment is collected.
Laboratory data collection at baseline
Laboratory tests performed at baseline include serum
creatinine, glucose, hemoglobin, thrombocytes, C-reactive
protein, and INR.
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Baseline CT acquisition and post-processing
Acquisition
On admission to the hospital, all patients undergo
NCCT, CTP and CTA. All imaging is performed on 40- to
320-detector CT scanners (Philips, Siemens, GE, Toshiba).
NCCT parameters are 120 kV, 300–375 mAs, and a 5 mm
reconstructed slice thickness.
CTP scans are generally performed with 80 kV and
150 mAs, and are also reconstructed as 5 mm contiguous
axial slices. Forty ml of non-ionic contrast material is
injected intravenously with a flow of 6 ml/s followed by
40 ml of saline with a flow of 6 ml/s. Images are acquired
every 2 seconds for 50 seconds after initiation of contrast
injection, followed by 1 image every 30 seconds from 60 to
210 seconds. CTP coverage ranges from 40 mm to full
brain coverage and covers at least the basal ganglia up to
the lateral ventricles to ensure that both Alberta Stroke
Program Early CT Score (ASPECTS) levels are included
[20-22]. CTP coverage can be lowered to cover the cerebel-
lum to the occipital lobes if a stroke in the posterior circu-
lation is expected, covering all three levels of the posterior
circulation ASPECTS (pcASPECTS) [17].
For the CTA, from aortic arch to cranium vertex, 50–70 ml
of non-ionic contrast material is injected intravenously
with a flow of 6 ml/s followed by 40 ml of saline with a
flow of 6 ml/s. The CTA scan delay after intravenous
contrast injection is calculated for each patient individually
from time to peak arterial enhancement on CTP, or by a
trigger based on Hounsfield unit threshold measurement
of contrast enhancement in the aortic arch.
Post-processing
The scan data from all participating hospitals are
collected centrally in the University Medical Center
Utrecht. Post-processing of the CTP and CTA scans is
performed using commercially available software on an
Extended Brilliance Workstation (version 4.5, Philips
Healthcare).
The software for CT perfusion post-processing has
been validated previously, and applies Gaussian curve
fitting by least mean squares to obtain mathematical de-
scriptions of the time-enhancement curves [4,23-25].
After calculation of the cerebral blood volume (CBV)
from the area under the time attenuation curve, the
mean transit time (MTT) is computed by using a decon-
volution operation [26]. Subsequently, cerebral blood
flow (CBF) is calculated according to the central volume
principle (CBF = CBV/MTT). Based upon previously re-
ported MTT and CBV thresholds, threshold-defined
penumbra and infarct core maps are calculated as well
as the penumbra/infarct core index [4]. The total ischae-
mic area is defined as a relative measure of MTT ≥145%
Figure 1 Study procedures and outcomes.
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compared to the contralateral (unaffected) hemisphere.
Within this ischaemic area, the infarct core is separated
from the penumbra by an absolute threshold value of
CBV <2.0 ml/100 g.
For the CTA, thin slice data is reviewed, with inter-
active maximum intensity projection (MIP) and multi-
planar reconstruction (MPR) possibilities, to assess the
anatomy and pathology of the extracranial and intracra-
nial vessels. Additional automated vessel segmentation is
performed for the carotid and vertebral arteries to assess
the degree of stenosis.
Baseline CT imaging data collection
All admission scans are assessed by an observer with at
least five years of experience in neurovascular imaging
(from a pool of three observers). Except for the side of
symptoms, observers are blinded for all clinical informa-
tion, including follow-up scans and clinical outcome.
For NCCT, presence of a hyperdense vessel sign is
determined and early ischaemic changes are assessed
with ASPECTS or pcASPECTS [12,20-22]. An area is
considered ischaemic on NCCT if there is parenchymal
hypoattenuation with or without swelling of the brain
[21,22]. Areas with isolated cortical swelling, but without
hypoattenuation, are not considered ischaemic [22].
Presence of haemorrhage, atrophy, white matter lesions,
or old infarct is also noted. On CTA source images
(CTA-SI), areas with diminished contrast enhancement
are considered ischaemic and are assessed with (pc)AS-
PECTS [12]. Next, the CTA is evaluated for location and
extent of arterial occlusion, leptomeningeal collateral cir-
culation, circle of Willis configuration, presence of dis-
section or sinus thrombosis, as well as presence and
degree of carotid or vertebrobasilar stenosis, and pres-
ence of intracranial atherosclerosis. Measurement of ca-
rotid or vertebrobasilar stenosis is performed according
to the NASCET method [27]. For CTP, presence of a
perfusion deficit is visually assessed on CBV, CBF, MTT,
time to peak (TTP), and penumbra/infarct core maps,
and evaluated with (pc)ASPECTS [11,28]. Reliability of
ASPECTS has been shown to be fair for NCCT, moder-
ate for CTA-SI and excellent for CTP [29], and inter-
observer agreement is excellent for assessment of site of
occlusion, good for collateral circulation, and good to
excellent for carotid stenosis [15,30].
Follow-up clinical and laboratory data collection
Follow-up clinical data collection
Temperature data is collected on day 1 to 3 after admis-
sion, and blood pressure and pulse rate on day 3. In case
of clinical deterioration, severity of the worsening symp-
toms is determined by a new NIHSS assessment (plus an
additional NCCT). At discharge, information on the
final diagnosis, flow territory, and cause of ischaemia
(such as large vessel disease, cardiac origin, dissection,
etc.) is collected. Clinical outcome is assessed with the
mRS at 90 days [31]. At 90 days, the Barthel Index and
EQ-5D are also collected [32,33].
Follow-up laboratory data collection
Laboratory tests performed on day 1 include (fasting)
glucose, HbA1c, HDL- and LDL-cholesterol, and triglyc-
erides. On day 3, data on serum creatinine, glucose
(non-fasting), and C-reactive protein are collected.
Follow-up imaging data collection
When possible, patients undergo follow-up CT imaging
3 days after admission, or earlier if patients are dis-
charged. Standard follow-up imaging consists of NCCT,
CTP and CTA with an imaging protocol identical to the
baseline imaging protocol. Radiological evidence of an
infarct is determined on the follow-up NCCT. If an in-
farct is present, final infarct volume is calculated and
(pc)ASPECTS is allocated. Any visible haemorrhage is
classified according to the ECASS classification [34]. Re-
perfusion is evaluated on the CTP and recanalisation on
the CTA. NCCT suffices if there is any reason not to ad-
minister intravenous contrast material. MRI can also
serve as follow-up imaging if clinically indicated
(preferably with diffusion-weighted, T2-FLAIR and T2-
weighted images, and MR angiography). In case of clinical
deterioration, a NCCT is performed to detect intracranial
haemorrhage (plus an additional NIHSS).
Study outcome measures
The primary outcome measure of this study is poor clin-
ical outcome assessed by the mRS at 90 days [31]. Col-
lection of the 90 day mRS is performed by a trained
research nurse or neurologist by telephone interview
[35]. A score of 0–2 represents good outcome, and a
score of 3–6 represents poor outcome [36]. Secondary
outcome measures include infarct size, symptomatic
and/or asymptomatic haemorrhage on follow-up NCCT,
reperfusion on follow-up CTP, recanalisation on follow-
up CTA, and Barthel Index and EQ-5D at 90 days.
Data entry and monitoring
Individual clinical and laboratory patient data is col-
lected by the local investigators and supporting staff in
the participating hospitals, and entered in a password-
protected electronic online case report form. Participat-
ing centres can only access patient data from patients
included in their own specific hospital. Prior to access to
the online case report form, all investigators are trained
in its use. To minimise missing or wrong (implausible)
data, investigators in the coordinating centre check
the database and missing values are retrieved where
possible.
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Analysis
Candidate predictors
Prediction models will be developed to investigate the
primary study outcome. In these models, we only in-
clude variables with an expected strong predictive value
for the outcome based on prior literature. Candidate
predictors that will be included in the prediction models
are divided into 3 groups: (1) patient characteristics and
NCCT, (2) CTA, and (3) CTP predictors.
1) Patient characteristics include age [37-39], stroke
severity (NIHSS) [38-40], time from symptom onset
to imaging, mRS prior to current stroke symptoms
[19], admission glucose level [41-43], and treatment
(yes/no for IV-rtPA/IAT/mechanical thrombectomy)
[44,45]. NCCT predictors are early ischaemic
changes (ASPECTS or pcASPECTS) [17,20,21], and
presence of a hyperdense vessel sign [19,46].
2) CTA predictors include ischaemic changes on
CTA-SI (ASPECTS or pcASPECTS) [12,13,17],
location and extent of arterial occlusion [16],
leptomeningeal collaterals [15,47], and presence
of severe ipsilateral carotid or vertebrobasilar artery
stenosis (>70%) or occlusion [48].
3) CTP predictors include perfusion deficits on CBV
and MTT maps (ASPECTS or pcASPECTS) [11],
and penumbra/infarct core index [4].
Model derivation
For the development of the prediction rule, three logistic
regression models will be developed in the derivation co-
hort consisting of 60% of the study population. Selection
of patients for the derivation cohort based on date of
inclusion. The first model will include patient character-
istics and NCCT parameters (Model A), reflecting the
situation in which CTP and CTA are not performed as
part of standard stroke workup. The second model will
consist of Model A + CTA predictors (Model B). The
third model will include Model B + CTP predictors
(Model C). Model selection and shrinkage of the model
coefficients will be performed [49]. The optimal penalty
factor will be determined with bootstrapping. Single
imputation will be used to decrease missing values. In
addition to true missing values, biologically improbable
values are also considered missing values. To minimise
the effect of outliers, continuous predictors will be trun-
cated at the 1st and 99th percentile [49].
Model validation
Model performance will be validated in the remaining
40% of the study population. Discrimination of the
models, i.e. the ability of the models to discriminate be-
tween patients with good and patients with poor outcome,
will be assessed with receiver operator characteristics
(ROC) analysis and corresponding area under the curve
(AUC) [50]. Calibration of the models, i.e. agreement be-
tween predicted outcomes and observed outcomes, will be
evaluated with calibration plots. In these plots, patients
are divided into quantiles according to their predicted risk.
For each quantile, the mean predicted probability is com-
pared to the mean observed outcome. Goodness-of-fit will
be tested with Hosmer-Lemeshow tests. Likelihood ratio
tests will be used to compare the difference in the models
for statistical significance. Superiority of the models will
be determined by using a combination of the results of the
ROC analyses, calibration plots and Hosmer-Lemeshow
tests, and likelihood ratio tests. A nomogram or score
chart will be developed for the best model to facilitate use
by clinicians.
Sample size
Based on previously published data on acute stroke in
The Netherlands, we expect approximately half of the
1500 patients to have a poor clinical outcome [51]. Hence,
in the derivation cohort consisting of 900 patients, we an-
ticipate a poor outcome in about 450 patients. In total, we
plan to include 15 variables in the most extensive model
(model C). We are able to reliably estimate the weight of
the predictors, as we have more than the (arbitrary)
amount of 10 events per predictor, allowing for enough
power for unexpected findings [52]. As we expect about
half of the patients to undergo some form of treatment
(IV-rtPA/IAT/mechanical thrombectomy) we still have
enough power to assess outcome in both the treatment
and non-treatment group [53]. The large study size also
ensures sufficient numbers for subgroup analyses, such as
stroke subtype, posterior circulation stroke, and stroke
complications.
Ethical considerations
The medical ethics committee of the University Medical
Center Utrecht approved the DUST. The study is con-
ducted according to the principles of the Declaration of
Helsinki and in accordance with the Dutch Medical
Research Involving Human Subjects Act. Patients are
only included in the DUST after written informed con-
sent is obtained from the patient or his/her legal repre-
sentative. Clinical data collection, laboratory testing, and
CT imaging at admission is performed as part of the
routine clinical work-up of stroke patients. Informed
consent is obtained before any further study related tests
or procedures are performed. Because stroke patients
may have a compromised ability to consent, the capacity
to consent is established first. In patients with a compro-
mised ability to consent, written informed consent is ob-
tained from their legal representative. Patients who die
before informed consent can be obtained are an excep-
tion. Because it is undesirable to burden the relatives
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with this request, the medical ethics committee waived
the need for informed consent in these patients.
Discussion
Prediction of clinical outcome in patients with symp-
toms of acute ischaemic stroke is not easy when based
on patient characteristics and NCCT alone. To the best
of our knowledge, the combined prognostic value of
CTP and CTA parameters in addition to clinical and
NCCT parameters has never been investigated in one
single study.
In our study design we aim to resemble clinical prac-
tice as much as possible for the sake of clinical applic-
ability and generalizability. Our study domain consists of
patients with a suspected acute ischaemic stroke at the
time of admission to the hospital, and therefore patients
with an unknown time of symptom onset, such as wake-
up strokes, and patients who turn out to have a stroke
mimic, are also included. As treatment decisions are
made in the acute stage when time is critical, prediction
of outcome as guideline for further treatment is needed
for all patients who are suspected of acute ischaemic
stroke, and not just for selected patients with middle
cerebral artery stroke who are eligible for treatment. The
large study population enables analysis of sufficient can-
didate predictors, and also permits further division, such
as between anterior and posterior circulation strokes
and whether treatment is given or not. The candidate
predictors selected for our prediction models can be de-
termined quickly in the clinical setting, enabling their
use in the acute stage. For this multicentre study CT im-
aging is performed on scanners from different vendors.
While this may result in more variation in the imaging
results, it improves generalizability to other hospitals,
which is of major importance for prediction studies.
Imaging assessment is performed by a single experi-
enced observer, which reflects the clinical practice of
most hospitals. Lastly, while many studies use surrogate
endpoints such as infarct volume or recanalization, using
clinical outcome at 90 days remains the most relevant out-
come for stroke patients.
In conclusion, this study will provide insight in the
added prognostic value of CTP and CTA parameters in
outcome prediction of acute stroke patients. The predic-
tion models that are developed in this study may guide
future treatment decisions in the acute stage.
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